Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

Amgen Inc

Healthcare US AMGN

375.43USD
-1.54(0.41%)

Last update at 2026-03-10T20:00:00Z

Day Range

372.74379.26
LowHigh

52 Week Range

205.30324.86
LowHigh

Fundamentals

  • Previous Close 376.97
  • Market Cap161032.42M
  • Volume2283451
  • P/E Ratio43.70
  • Dividend Yield2.94%
  • EBITDA11658.00M
  • Revenue TTM29532.00M
  • Revenue Per Share TTM55.15
  • Gross Profit TTM 19917.00M
  • Diluted EPS TTM6.87

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 7346.00M 6701.00M 8133.00M 9138.00M 9545.00M
Minority interest - - - - -
Net income 6552.00M 5893.00M 7264.00M 7842.00M 8394.00M
Selling general administrative 5414.00M 5368.00M 5730.00M 5150.00M 5332.00M
Selling and marketing expenses - - - - -
Gross profit 19917.00M 19525.00M 19265.00M 19006.00M 19646.00M
Reconciled depreciation 3417.00M 3398.00M 3601.00M 2206.00M 1946.00M
Ebit 5335.00M 6005.00M 5794.00M 9674.00M 8991.00M
Ebitda 8752.00M 9403.00M 9395.00M 10427.00M 10937.00M
Depreciation and amortization 3417.00M 3398.00M 3601.00M 753.00M 1946.00M
Non operating income net other -814.00000M 259.00M 256.00M 753.00M 674.00M
Operating income 5335.00M 6005.00M 5794.00M 9674.00M 10263.00M
Other operating expenses 16757.00M 16835.00M 16285.00M 13688.00M 13484.00M
Interest expense 1406.00M 1197.00M 1262.00M 1289.00M 1392.00M
Tax provision 794.00M 808.00M 869.00M 1296.00M 1151.00M
Interest income - - 256.00M 753.00M 674.00M
Net interest income -1406.00000M -1197.00000M -1006.00000M -536.00000M -718.00000M
Extraordinary items - - - - -
Non recurring - 1505.00M - - -
Other items - - - - -
Income tax expense 794.00M 808.00M 869.00M 1296.00M 1151.00M
Total revenue 26323.00M 25979.00M 25424.00M 23362.00M 23747.00M
Total operating expenses 10351.00M 10381.00M 10126.00M 9332.00M 9383.00M
Cost of revenue 6406.00M 6454.00M 6159.00M 4356.00M 4101.00M
Total other income expense net 2011.00M 696.00M 2339.00M -536.00000M -718.00000M
Discontinued operations - - - - -
Net income from continuing ops 6552.00M 5893.00M 7264.00M 7842.00M 8394.00M
Net income applicable to common shares 6552.00M 5893.00M 7264.00M 7842.00M 8394.00M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 97154.00M 65121.00M 61165.00M 62948.00M 59707.00M
Intangible assets 32641.00M 16080.00M 15182.00M 16587.00M 19413.00M
Earning assets - - - - -
Other current assets 281.00M 2388.00M 2367.00M 2079.00M 1888.00M
Total liab 90922.00M 61460.00M 54465.00M 53539.00M 50034.00M
Total stockholder equity 6232.00M 3661.00M 6700.00M 9409.00M 9673.00M
Deferred long term liab - - - - 606.00M
Other current liab 15359.00M 12524.00M 10731.00M 10141.00M 8511.00M
Common stock 33070.00M 32514.00M 32096.00M 31802.00M 31531.00M
Capital stock 33070.00M 32514.00M 32096.00M 31802.00M 31531.00M
Retained earnings -26549.00000M -28622.00000M -24600.00000M -21408.00000M -21330.00000M
Other liab - 7880.00M 9059.00M 8991.00M 9861.00M
Good will 18629.00M 15529.00M 14890.00M 14689.00M 14703.00M
Other assets - 2158.00M 6524.00M 1258.00M 955.00M
Cash 10944.00M 7629.00M 7989.00M 6266.00M 6037.00M
Cash and equivalents - - - - -
Total current liabilities 18392.00M 15687.00M 12184.00M 11653.00M 12835.00M
Current deferred revenue - - - - -
Net debt 53669.00M 31316.00M 25320.00M 26720.00M 23866.00M
Short term debt 1443.00M 1591.00M 87.00M 91.00M 2953.00M
Short long term debt 1443.00M 1591.00M 87.00M 91.00M 2953.00M
Short long term debt total 64613.00M 38945.00M 33309.00M 32986.00M 29903.00M
Other stockholder equity - 21709.00M 18202.00M -985.00000M -528.00000M
Property plant equipment - 5427.00M 5184.00M 4889.00M 4928.00M
Total current assets 30332.00M 22186.00M 19385.00M 21144.00M 18440.00M
Long term investments - - - - 799.00M
Net tangible assets - -27948.00000M -23372.00000M -21867.00000M -24443.00000M
Short term investments 10944.00M 1676.00M 48.00M 4381.00M 2874.00M
Net receivables 7942.00M 5563.00M 4895.00M 4525.00M 4057.00M
Long term debt 63170.00M 37354.00M 33222.00M 32895.00M 26950.00M
Inventory 9518.00M 4930.00M 4086.00M 3893.00M 3584.00M
Accounts payable 1590.00M 1572.00M 1366.00M 1421.00M 1371.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity 0.00000M - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -289.00000M -231.00000M -796.00000M -985.00000M -528.00000M
Additional paid in capital 0.00000M - - - -
Common stock total equity - 32514.00M 32096.00M 31802.00M 31531.00M
Preferred stock total equity - - - - -
Retained earnings total equity - -28622.00000M -24600.00000M -21408.00000M -21330.00000M
Treasury stock 0.00000M - - - -
Accumulated amortization - - - - -
Non currrent assets other 9611.00M 5899.00M 6524.00M 5639.00M 2223.00M
Deferred long term asset charges - - - - -
Non current assets total 66822.00M 42935.00M 41780.00M 41804.00M 41267.00M
Capital lease obligations - - - - -
Long term debt total - 37354.00M 33222.00M 32895.00M 26950.00M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -2588.00000M -6044.00000M 733.00M -4718.00000M 19996.00M
Change to liabilities - 268.00M -567.00000M 779.00M -25.00000M
Total cashflows from investing activities -26204.00000M -6044.00000M 733.00M -5401.00000M 5709.00M
Net borrowings - 6622.00M 795.00M 2464.00M -4514.00000M
Total cash from financing activities 21048.00M -4037.00000M -8271.00000M -4867.00000M -15767.00000M
Change to operating activities - 1019.00M 119.00M 1112.00M 406.00M
Net income 6717.00M 6552.00M 5893.00M 7264.00M 7842.00M
Change in cash 3315.00M -360.00000M 1723.00M 229.00M -908.00000M
Begin period cash flow 7629.00M 7989.00M 6266.00M 6037.00M 6945.00M
End period cash flow 10944.00M 7629.00M 7989.00M 6266.00M 6037.00M
Total cash from operating activities 8471.00M 9721.00M 9261.00M 10497.00M 9150.00M
Issuance of capital stock - - - - -
Depreciation 4071.00M 3417.00M 3398.00M 3601.00M 2206.00M
Other cashflows from investing activities - -3721.00000M 1613.00M -75.00000M -13669.00000M
Dividends paid 4556.00M 4196.00M 4013.00M 3755.00M 3509.00M
Change to inventory 491.00M -742.00000M -165.00000M -215.00000M -66.00000M
Change to account receivables -1015.00000M -746.00000M -429.00000M -427.00000M -504.00000M
Sale purchase of stock 0.00000M -6360.00000M -4975.00000M -3486.00000M -7702.00000M
Other cashflows from financing activities 27058.00M 6519.00M -78.00000M -90.00000M -42.00000M
Change to netincome - 485.00M 3368.00M -152.00000M 205.00M
Capital expenditures 1112.00M 936.00M 880.00M 608.00M 618.00M
Change receivables - -746.00000M -429.00000M -427.00000M -504.00000M
Cash flows other operating - 487.00M 1472.00M -353.00000M -136.00000M
Exchange rate changes - - - - -
Cash and cash equivalents changes - -360.00000M 1723.00M 229.00M -908.00000M
Change in working capital -484.00000M -733.00000M -1194.00000M -216.00000M -731.00000M
Stock based compensation 431.00M 401.00M 341.00M 330.00M 308.00M
Other non cash items -991.00000M 1282.00M 1276.00M -195.00000M -186.00000M
Free cash flow 7359.00M 8785.00M 8381.00M 9889.00M 8532.00M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - General

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AMGN
Amgen Inc		 -1.54 0.41% 375.43 43.70 13.77 5.08 22.99 6.99 13.31
LLY
Eli Lilly and Company		 -7.04 0.70% 1001.35 78.14 31.95 16.34 45.83 16.65 54.36
JNJ
Johnson & Johnson		 1.12 0.46% 243.71 29.17 14.33 3.74 5.18 3.80 15.22
ABBV
AbbVie Inc		 -0.44 0.19% 227.01 61.52 14.86 5.62 51.62 6.76 20.58
MRK
Merck & Company Inc		 -0.02 0.02% 117.09 59.83 12.33 4.50 6.47 4.94 23.79

Reports Covered

Stock Research & News

View All

Profile

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Amgen Inc

One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799

Key Executives

Name Title Year Born
Mr. Robert A. Bradway Chairman, CEO & Pres 1963
Mr. Peter H. Griffith Exec. VP & CFO 1959
Mr. Esteban Santos Exec. VP of Operations 1968
Dr. David M. Reese M.D. Exec. VP of R&D 1963
Mr. Murdo Gordon Exec. VP of Global Commercial Operations 1967
Ms. Linda H. Louie VP of Fin. & Chief Accounting Officer NA
Mr. Mike Zahigian Sr. VP & Chief Information Officer NA
Mr. Arvind Sood VP of Investor Relations NA
Mr. Jonathan P. Graham Exec. VP, Gen. Counsel & Sec. 1961
Ms. Nancy A. Grygiel Sr. VP of Worldwide Compliance & Bus. Ethics and Chief Compliance Officer 1968

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.